Jonathan C Li

Title: Innovations by Jonathan C Li in Cancer Treatment

Introduction

Jonathan C Li is a prominent inventor based in Rockville, MD (US), known for his significant contributions to cancer treatment through innovative bi-specific binding molecules. With a total of 5 patents, his work focuses on developing advanced therapeutic agents that target cancer antigens effectively.

Latest Patents

One of his latest patents involves Tri-specific binding molecules that specifically bind to multiple cancer antigens. This invention relates to multi-chain polypeptide molecules that possess three Binding Domains, enabling them to mediate coordinated binding to three epitopes. The Tri-Specific Binding Molecule is designed to immunospecifically bind to an epitope of a first Cancer Antigen, an epitope of a second Cancer Antigen, and an epitope of a molecule expressed on the surface of an immune system effector cell. This capability allows for the localization of immune system effector cells to cancer cells, facilitating their destruction.

Another notable patent is for bi-specific monovalent diabodies that can bind to gpA33 and CD3. This invention includes bi-specific monovalent diabodies composed of two polypeptide chains, each possessing binding sites specific for CD3 and gpA33. Additionally, the invention encompasses bi-specific monovalent Fc diabodies, which are composed of three polypeptide chains and also target these two epitopes. These innovative diabodies are intended for use in pharmaceutical compositions aimed at treating cancer and other diseases.

Career Highlights

Jonathan C Li is currently associated with Macrogenics, Inc., where he continues to advance his research in the field of cancer therapeutics. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.

Collaborations

Some of his notable coworkers include Paul A Moore and Leslie Sydnor Johnson, who contribute to the collaborative efforts in developing innovative cancer treatments.

Conclusion

Jonathan C Li's innovative work in developing tri-specific and bi-specific binding molecules represents a significant advancement in cancer treatment. His contributions are paving the way for new therapeutic strategies that could enhance the efficacy of cancer therapies.